41 results about "Angiogenic Process" patented technology

Q is —N=or CR2 X is S, O or NOR3 Y is —O—, —S—, —SO— or —SO2—R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl groupR2 is H or a substituentR3 is H, or —C(O)R4 R4 is a substituted or unsubstituted aliphatic or aromatic groupn is an integer from 0 to 1Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine / threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

The present invention relates to chemical compounds having a general formula Iwherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

There is provided a simplified and inexpensive method for the in-vitro identification, isolation and culture of human vasculogenic progenitor cells. The method and the progenitor cells isolated thereby can be used for in-vitro vascular engineering, treatment of congenital and acquired vascular and hematological abnormalities, for evaluation and development of drugs affecting vasculo- and angiogenic processes, and for further investigation into tissue differentiation and development.

The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.

The present invention provides a compound of formula (I), wherein Q is -N= or CR2; X is S, O or NOR3; Y is -O-, S-, -SO- or -SO2-; R and R1 are independently is H, substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl-yl; group; R2 is H or a substituent; R3 is H, or -C(O)R4; R4 is substituted or unsubstituted Substituted aliphatic or aromatic groups; n is an integer 0-1. Compounds of formula (I) and their physiologically acceptable salts are inhibitors of serine / threonine and tyrosine kinase activity. Several tyrosine kinases whose activity can be inhibited by these compounds are involved in the angiogenic process. Thus, these chemical compounds are able to ameliorate disease states in which angiogenesis or endothelial cell proliferation is a factor. These compounds are useful in the treatment of cancer and hyperproliferative diseases.

The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).

A simplified and inexpensive method for the in-vitro identification, isolation and culture of human vasculogenic progenitor cells is provided. The method and the progenitor cells provided herein can be used for in-vitro vascular engineering, treatment of congenital and acquired vascular and hematological abnormalities, for evaluation and development of drugs affecting vasculo- and angiogenic processes, and for further investigation into tissue differentiation and development.

This invention provides isolated nucleic acid and amino acid sequences encoding VG5Q, a novel angiogenic growth factor protein with pro-angiogenic activity, a forkhead-associated domain, a G-patch domain; characteristic subcellular localization in an in vitro Matrigel model of angiogenesis: towards the cell periphery in early stages of tubulogenesis, between cells in newly formed endothelial tubes, and no nuclear staining after 24 hours; is expressed in endothelial cells; is secreted during angiogenesis; and interacts with TWEAK. The invention also provides for expression vectors containing nucleic acid sequences encoding VG5Q protein, and host cells containing one or more expression vectors for the recombinant expression of VG5Q. The invention also provides for methods of using VG5Q for the diagnosis and treatment of angiogenesis-mediated diseases or disorders.

The present invention describes novel compounds of the formula:(Q)d-Ln-Ch,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.

The invention relates to a novel synergetic medical compound being capable of suppressing growth of tumors, which consists of an enediyne drug and an alkylated chemotherapeutic drug, i.e. lidamycin and temodar; relevant researches prove that the medical compound can synergetically resist the multiplication of the tumor cells, induce apoptosis and suppress angiogenesis; in vivo test has an obvious curative effect on nude mice transplanted tumor of the human neuroglioma U87 cells. The medical compound has an enhanced function of suppressing the growth of tumors and angiogenesis in tumor tissues, thus displaying a synergetic tumor suppressing effect and having good application prospect.

The invention provides an application of a composite of sweet wormwood herb and turtle shell in preparing antitumor medicine. The composite comprises five traditional Chinese medicines, namely sweet wormwood herb, Colla Carapacis Trionycis, rehmanniae, rhizoma anemarrhenae and Tree peony bark, and preparation form thereof is solid. The composite provided by the invention has activity in antitumorchronic inflammation reaction, can be used for treating tumor inflammation reaction and angiogenesis process, and can be used as adjuvant therapy medicine and increase antitumor therapy of chemotherapeutics. The invention utilizes the theoretical background that tumors can generate various cells and cytokines by inducing under hypoxia microenvironment, researches and illustrates the miracle performance of traditional Chinese medicine, namely entering into collaterals for eliminating pathogens and leading pathogens out, provides important accordance for exploring new clinical value of famous and high-quality traditional Chinese medicine recipe, and points out new and important direction for developing traditional Chinese medicine theory.

The invention provides an application of a composite of sweet wormwood herb and turtle shell in preparing antitumor medicine. The composite comprises five traditional Chinese medicines, namely sweet wormwood herb, Colla Carapacis Trionycis, rehmanniae, rhizoma anemarrhenae and Tree peony bark, and preparation form thereof is solid. The composite provided by the invention has activity in antitumor chronic inflammation reaction, can be used for treating tumor inflammation reaction and angiogenesis process, and can be used as adjuvant therapy medicine and increase antitumor therapy of chemotherapeutics. The invention utilizes the theoretical background that tumors can generate various cells and cytokines by inducing under hypoxia microenvironment, researches and illustrates the miracle performance of traditional Chinese medicine, namely entering into collaterals for eliminating pathogens and leading pathogens out, provides important accordance for exploring new clinical value of famous and high-quality traditional Chinese medicine recipe, and points out new and important direction for developing traditional Chinese medicine theory.

The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.

The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.